Adverum Bio Stock (NASDAQ:ADVM)
Previous Close
$6.25
52W Range
$6.00 - $29.70
50D Avg
$7.48
200D Avg
$10.16
Market Cap
$128.35M
Avg Vol (3M)
$187.92K
Beta
1.01
Div Yield
-
ADVM Company Profile
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
ADVM Performance
Peer Comparison
Ticker | Company |
---|---|
MREO | Mereo BioPharma Group plc |
MGTX | MeiraGTx Holdings plc |
RCKT | Rocket Pharmaceuticals, Inc. |
STOK | Stoke Therapeutics, Inc. |
AVTE | Aerovate Therapeutics, Inc. |
ACRV | Acrivon Therapeutics, Inc. Common Stock |
ONCT | Oncternal Therapeutics, Inc. |
ABSI | Absci Corporation |
BCEL | Atreca, Inc. |
GLMD | Galmed Pharmaceuticals Ltd. |
PASG | Passage Bio, Inc. |
ANTX | AN2 Therapeutics, Inc. |
KOD | Kodiak Sciences Inc. |
AFMD | Affimed N.V. |
RZLT | Rezolute, Inc. |
RYTM | Rhythm Pharmaceuticals, Inc. |
SLDB | Solid Biosciences Inc. |
ADAG | Adagene Inc. |
KZR | Kezar Life Sciences, Inc. |
FIXX | Q32 Bio Inc. |
QURE | uniQure N.V. |